UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 13, 2013

 

AMICUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Registrant’s telephone number, including area code: (609) 662-2000

 

 

(Former name or former address if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 5.07  Submission of Matters to a Vote of Security Holders.

 

At the 2013 Annual Meeting of Stockholders of Amicus Therapeutics, Inc. (the “Company”) held on June 13, 2013, the Company’s stockholders elected John F. Crowley, Margaret G. McGlynn, R. Ph., Michael G. Raab and Glenn P. Sblendorio as Class III directors each to serve a three-year term expiring at the 2016 Annual Meeting of Stockholders or until their respective successors have been elected, and Robert Essner and Ted W. Love, M.D. as Class I directors each to serve a one-year term expiring at the 2014 Annual Meeting of Stockholders or until their respective successors have been elected. In addition, the stockholders (i) ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2013, (ii) voted to approve, on an advisory basis, the compensation paid to the Company’s named executive officers, and (iii) voted to approve, on an advisory basis, that the preferred frequency of advisory stockholder votes on executive compensation of the Company’s named executive officers should be every year.  The final voting results on these matters were as follows:

 

1.             Election of Directors

 

Nominee		Votes For		Votes Withheld		Broker Non-Votes
John F. Crowley		36,975,544		68,384		5,617,180
Robert Essner		36,987,984		55,944		5,617,180
Ted W. Love, M.D.		36,655,470		388,458		5,617,180
Margaret G. McGlynn, R.Ph.		33,235,898		3,808,030		5,617,180
Michael G. Raab		33,230,699		3,813,229		5,617,180
Glenn P. Sblendorio		36,992,580		51,348		5,617,180

 

2.                                      Ratification of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2013

 

Votes For		Votes Against		Votes Abstain		Broker Non-Votes
42,603,669		44,793		12,646		0

 

3.                                      Approval, on an advisory basis, of the Company’s executive compensation

 

Votes For		Votes Against		Votes Abstain		Broker Non-Votes
28,342,590		8,679,746		21,392		5,617,180

 

4.                                      Approval, on an advisory basis, of the frequency of future executive compensation advisory votes

 

Every 1 Year		Every 2 Years		Every 3 Years		Votes Abstain		Broker Non-Votes
18,877,801		235,874		17,836,707		93,546		5,617,180

 

In accordance with the results of this advisory vote, the Company’s Board of Directors has determined that the Company will hold an advisory vote on the compensation of the Company’s named executive officers every year.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

	AMICUS THERAPEUTICS, INC.
Date: June 18, 2013	By:	/s/ PETER M. MACALUSO
	Name:	Peter M. Macaluso
	Title:	Secretary

 

3